Back to Headlines
Health
Jun 07, 2026
Analyzed by GPT OSS 120B

Weekly Diabetes Jab Shows Major Blood‑Sugar Drop and Weight Loss

AI Summary
A phase‑3 trial of retatrutide, a once‑weekly triple‑hormone injection, cut HbA1c by up to 1.9 percentage points and produced up to 15 % body‑weight loss in type 2 diabetes patients after 40 weeks. The results suggest a potential new standard for combined glucose and weight management.

A phase‑3 trial of retatrutide, a once‑weekly triple‑hormone injection, showed patients with type 2 diabetes cut HbA1c by up to 1.9 percentage points and shed up to 15 % of body weight after 40 weeks.

Triple‑Hormone Mechanism Sets Retatrutide Apart

The drug combines analogues of GLP‑1, GIP and glucagon, targeting appetite, glucose regulation and energy expenditure simultaneously. Unlike Ozempic or Wegovy (GLP‑1 only) and Mounjaro (GLP‑1 + GIP), the added glucagon activity aims to boost metabolic rate.

Trial Numbers Reveal Double‑Digit HbA1c Cuts and 15% Weight Loss

  • 930 adults with type 2 diabetes, BMI ≥ 23, not on other diabetes meds.
  • Randomised to 4 mg, 9 mg or 12 mg retatrutide or placebo for 40 weeks.
  • HbA1c reduction: 1.7‑1.9 pp vs 0.8 pp placebo.
  • Weight loss: 11.5‑15.3 % vs 2.6 % placebo.
  • Improvements in cholesterol and blood pressure observed.
  • Serious adverse events in 14 participants (including 2 on placebo); most side effects were mild gastrointestinal issues.

Potential Shift in Diabetes‑Obesity Treatment Landscape

Experts say the dual impact on glycaemic control and weight could reshape management pathways. Dr Kath McCullough (Royal College of Physicians) called the results “life‑changing,” while Dr Marie Spreckley (University of Cambridge) cautioned that head‑to‑head data against existing agents are still needed.

For health systems such as the NHS, a drug delivering both outcomes may reduce long‑term cardiovascular complications and associated costs, but pricing and safety profiles will drive adoption.

Next Steps: Head‑to‑Head Comparisons and Long‑Term Safety

Further phase‑3 studies are planned to compare retatrutide directly with semaglutide and tirzepatide. Regulators will scrutinise the balance of metabolic benefits against gastrointestinal adverse events before approval.